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Skeletal muscle fatigue and post-exertional malaise are key symptoms of myalgic en-
cephalomyelitis (ME)/chronic fatigue syndrome (ME/CFS). We have previously shown that
AMP-activated protein kinase (AMPK) activation and glucose uptake are impaired in primary
human skeletal muscle cell cultures derived from patients with ME/CFS in response to elec-
trical pulse stimulation (EPS), a method which induces contraction of muscle cells in vitro.
The aim of the present study was to assess if AMPK could be activated pharmacologically
in ME/CFS. Primary skeletal muscle cell cultures from patients with ME/CFS and healthy
controls were treated with either metformin or compound 991. AMPK activation was as-
sessed by Western blot and glucose uptake measured. Both metformin and 991 treatment
significantly increased AMPK activation and glucose uptake in muscle cell cultures from
both controls and ME/CFS. Cellular ATP content was unaffected by treatment although ATP
content was significantly decreased in ME/CFS compared with controls. Pharmacological
activation of AMPK can improve glucose uptake in muscle cell cultures from patients with
ME/CFS. This suggests that the failure of EPS to activate AMPK in these muscle cultures is
due to a defect proximal to AMPK. Further work is required to delineate the defect and de-
termine whether pharmacological activation of AMPK improves muscle function in patients
with ME/CFS.
Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), is a long-term illness
affecting approximately 250000people in theU.K., andhas awide range of symptoms. The principal symp-
tom is unexplained persistent fatigue, lasting for at least 6 months, which cannot be alleviated by rest [1].
This is often accompanied by cognitive deficits, muscle weakness and sleep disturbances. Post-exertional
malaise, where symptoms are amplified or prolonged after minor exertion, is another key symptom of
ME/CFS [2].
AMP-activated protein kinase (AMPK) is a keymediator of the skeletal muscle response to exercise [3].
In response to an energy deficit, such as during muscle contraction, AMPK is activated resulting in the
switching off of ATP-consuming processes, and the switching on of ATP-generating processes. In skeletal
muscle, this includes an increase in the uptake of glucose into the muscle cell [4]. We have previously
shown that AMPK activation is impaired in primary human skeletal muscle cell cultures derived from
patients with ME/CFS in response to electrical pulse stimulation (EPS), a method which induces contrac-
tion of muscle cells in vitro [5]. This abnormality in AMPK activation also resulted in a failure to increase
glucose uptake into the cell in response to EPS.
AMPK is a heterotrimeric complex ofα,β and γ subunits. Multiple isoforms exist for each subunit and
some isoforms may be expressed in a cell-type or tissue-specific manner [6,7]. AMPK can be activated
allosterically, particularly by AMP or via activation of upstream kinases including liver kinase B1 (LKB1)
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and the Ca2+/calmodulin-dependent kinase kinase (CaMKK) [8]. AMPK can also be regulated by pharmacologi-
cal agents including metformin, which activates AMPK indirectly by inhibiting ATP synthesis. A number of small
molecule activators have been developed which bind directly to AMPK, resulting in allosteric activation of AMPK
[9].
The aim of the present study was to examine if AMPK can be modified by pharmacological treatment in primary
human skeletal muscle cell cultures derived from patients with ME/CFS. We used both an indirect activator of AMPK
(metformin) and a direct activator (Compound 991) to assess AMPK activation, glucose uptake and ATP content of
muscle cells.
Materials and methods
Study subjects
Muscle biopsies were obtained from 10 patients diagnosed with CFS and 7 healthy control subjects. Groups were
matched for age and comprised males and females. All subjects were recruited via the Newcastle NHS CFS Clinical
Service at the Newcastle Hospitals NHS Foundation Trust. All subjects fulfilled the Fukuda criteria [1] and provided
written informed consents. None had evidence of neurological deficit based on clinical assessment. The study was
approved by the Newcastle and North Tyneside Joint Ethics Committee.
General chemicals and reagents
Cell culture medium was obtained from Scientific Laboratory Supplies (U.K.). FBS and trypsin-EDTA were ob-
tained from Life Technologies (Paisley, U.K.). Chick embryo extract was purchased from Sera Labs International
(Sussex, U.K.). p-AMPKThr172 (40H9) and total AMPKα (F6) antibodies were obtained from New England Bio-
labs (Herts, U.K.) while β-actin (clone AC-15) was purchased from Sigma. Monoclonal mouse antihuman desmin
(D33) antibody was obtained from DAKO. Vector VIP HRP-substrate kit was obtained from Vector Laboratories.
2-Deoxy-D-[2,6-3H]glucose was purchased from Hartmann Analytic (Germany). Compound 991 was donated by
AstraZeneca. Metformin was obtained from Sigma.
Cell culture
Muscle biopsies were obtained from the vastus lateralis and muscle precursor cells isolated as described in detail
previously [5,10]. Myoblasts were cultured in Ham’s F10 medium supplemented with 20% (v/v) FBS and 2% (v/v)
chick embryo extract. At confluence, differentiation was induced by changing the media to minimal essential media
supplemented with 2% (v/v) FBS. All experiments were performed on day 7 differentiated myotubes, passage 7.
Western blotting
Cells were lysed in extraction buffer (100 mM Tris/HCl, pH 7.4, 100 mM KCl, 1 mM EDTA, 25 mM KF, 1 mM ben-
zamidine, 0.5 mM Na3VO4, 0.1% (v/v) Triton X-100, 1× protease inhibitor cocktail (Pierce) before sonicating for
10 s). Protein concentrations were determined spectrophotometrically at 595 nm by a Coomassie binding method
(Pierce). Ten microgram samples were prepared in Laemmli sample buffer (0.125 M Tris/HCl, pH 6.8, 4% (w/v) SDS,
20% (v/v) glycerol, 10% (v/v) 2-mercaptoethanol and 0.004% (w/v) Bromophenol Blue) and boiled for 5 min. Af-
ter separation on SDS/PAGE (10% gels), proteins were transferred on to PVDF membranes using a mini-Hoeffer wet
transfer system. After incubation with the appropriate antibodies, detection took place using ECL. p-AMPK antibody
was used at 1:1000 dilution while AMPKα was used at 1:2000 dilution. β-actin was used at 1:10000. Densitometry
was performed using a Bio-Rad Molecular Imager GS-800 calibrated densitometer and Quantity One software. De-
pending upon the exposure time, the AMPKα detected more than one isoform. Under these circumstances, the band
corresponding to the p-AMPK band was used to for densitometric analysis. All antibodies were obtained from New
England Biolabs.
ATP assay
Cellular ATP content of cells was assessed by ATP luciferase assay. After the indicated treatment times, medium was
removed and cells extracted in 0.1 M NaOH solution. A standard curve was generated using 1 mM ATP (Sigma)
diluted in 0.1 M NaOH and 20 μl each standard and sample were added in duplicate to a 96-well white luminescence
plate. A 50-μl aliquot of FL-AAM assay mix (Sigma) was added to 10 ml ATP assay buffer (0.1 M Tris, pH 7.75, 10
mM Mg-acetate, 1.8 mM EDTA, 0.6 g/l BSA) and 100 μl this solution was added to each well of the 96-well plate.
Luminescence was measured immediately and ATP content determined relative to the ATP standard curve. Protein
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Figure 1. Phosphorylation of AMPKThr172 was assessed by Western blot of myotubes after treatment
(A) 2 mM metformin for 16 h (B) 1 μM 991 for 2 h. Densitometry is expressed as a ratio of phosphorylated to total protein. Open
bar: untreated, closed bar: treated. *P<0.05, **P<0.01. n=7 controls and 8 CFS.
content of the extracted samples was measured spectrophotometrically at 595 nm by a Coomassie binding method
(Pierce).
Glucose uptake
Glucose uptake wasmeasured by incubating cells in tritiated 2-deoxyglucose after treatment with eithermetformin or
compound 991. After treatment, cells were incubated in Krebs’ buffer (136mM NaCl, 4.7 mM KCl, 1.25 mM MgSO4,
1.2 mM CaCl2, 20 mM HEPES, pH 7.4) with or without 100 nM insulin or cytochalasin B (10 μM) for 20 min; 0.1
mM 2-deoxyglucose and 0.5 μCi (2,6-3H) 2-deoxyglucose were added to each well and incubated for a further 10
min. The reaction was stopped by washing the plate rapidly in ice-cold PBS. Cells were lysed in 0.05% SDS before
scintillation counting and protein determination. The specific activity of the tritiated glucose was calculated before
it was added to the cells and this was used to calculate the nmol glucose incorporated into the cells over 1 min. Data
were normalized to total protein content and presented as pmol/min/mg.
Statistical analysis
All results are expressed asmean+− S.E.M. unlesswhere stated.Datawere analysedusing one-way or two-wayANOVA
where appropriate and, where significant, followed up by t test between groups. Statistical analyses were performed
using GraphPad Prism (California) software.
Results
Effect of metformin and 991 on AMPK activation
Skeletal muscle cells from seven healthy controls and eight CFS subjects were grown to confluence and allowed to dif-
ferentiate for 7 days. Cells were then treated with either 2 mM metformin for 16 h or 1 μM 991 for 2 h prior to protein
extraction and Western blotting. Figure 1A shows thatmetformin treatment significantly increasedAMPK activation,
as measured by phosphorylation of AMPK on residue Thr172, in both control (P<0.01) and CFS (P<0.05) myotubes,
compared with untreated. Compound 991 treatment had a similar effect, significantly increasing AMPK activation
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 2. Glucose uptake was measured in control and CFS myotubes after treatment
(A) 2 mMmetformin for 16 h. Open bar: untreated, closed bar: insulin treatment, hatched bar: metformin treatment. (B) 0.1 and 1 μM
991 for 2 h. Open bar: untreated, closed bar: insulin treatment, hatched bar: 0.1 μM 991, grey bar: 1 μM 991. *P<0.05, **P<0.01,
***P<0.0005. n=7 controls and 8 CFS assayed at least in duplicate.
0.0
0.2
0.4
0.6
0.8
1.0
Control   CFS
* **
C
el
lu
la
r 
A
TP
 c
on
te
nt
0.0
0.2
0.4
0.6
0.8
1.0
Control    CFS
* *
C
el
lu
la
r 
A
TP
 c
on
te
nt
(A) (B)
Figure 3. Cellular ATP content measured in control and CFS myotubes after treatment
(A) 2 mM metformin for 16 h. (B) 1 μM 991 for 2 h. Open bar: untreated, closed bar: treated. Data were normalized to untreated.
*P<0.05, **P<0.01. n=7 control and 8 CFS assayed in duplicate.
over untreated myotubes in both control and CFS (P<0.05, both) (Figure 1B). ACC phosphorylation increased in a
dose-dependent manner in response to compound 991 (see Supplementary Figure S1).
Effect of metformin and 991 on glucose uptake
Activation of AMPK would be expected to lead to an increase in glucose uptake. Figure 2A shows that metformin
treatment significantly increased glucose uptake in both control and CFS cells, and the effect was comparable with
that of insulin. In controls, metformin increased glucose uptake from 632.8 +− 50.4 to 1014 +− 79.2 pmol/mg/min
(P<0.0005), while in CFS, glucose uptake increased from 576.4 +− 26.5 to 715 +− 21.2 pmol/mg/min (P<0.0005).
Compound 991 treatment also increased glucose uptake at concentrations of 0.1 and 1 μM in both control and CFS
cells (Figure 2B). In controls, glucose uptake increased from 802.2 +− 59.4 to 963.9 +− 37.9 pmol/mg/min and 1084.3+− 44.9 pmol/mg/min (P<0.05) for 0.1 and 1 μM 991, respectively. Compound 991 increased glucose uptake from
633.8 +− 56.8 to 933.7 +− 93.3 pmol/mg/min (P<0.01) and 913.9 +− 105.7 pmol/mg/min (P<0.01) for 0.1 and 1 μM,
respectively. In both control and CFS cells, the effect of 991 treatment was comparable with that of insulin.
Effect of metformin and 991 on cellular ATP content
Treatment with either metformin or 991 did not reduce cellular ATP content (Figure 3). However, ATP content is
significantly decreased in muscle cell cultures from CFS compared with control (P<0.05), regardless of treatment.
Discussion
The present study demonstrates that AMPK and subsequent downstream effects can be activated by both an indirect
(metformin) and direct (compound 991) activator of AMPK in skeletal muscle cells from patients with ME/CFS. This
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is in contrast with our previous study of the same muscle cell cultures which showed that EPS-mediated contraction
failed to activate AMPK and glucose uptake in skeletal muscle cells from patients with ME/CFS [5]. Together, these
findings point to a signalling defect proximal to AMPK, and further studies are underway to explore the expression
and function of the key proximal signallingmolecules in theME/CFS cultures. This is the first report to show that 991
is active in human skeletal muscle cell cultures. Compound 991 has previously been shown to increase AMPK activity
and glucose uptake in isolated rat skeletal muscle [11]. These effects are ablated in AMPKα1-/α2 knockout mouse
myotubes, suggesting that 991 acts specifically via AMPK. Further evidence for the specificity of 991 for AMPK is
indicated by a screen of 991 against a panel of protein kinases in cell-free assays. This showed that 991 enhances
AMPK activity while it has no effect on upstream kinases including LKB1 and CaMKK [12].
Current evidence indicates that AMPK activation increases glucose uptake through activation of AS160 and glu-
cose transporter translocation to the cell membrane [13]. As part of our ongoing work, we are exploring the fate of the
AMPK-mediated glucose uptake with a particular focus on glucose oxidation and glycolysis in the ME/CFS cultures.
The regulation of AMPK is complex. As well as allosteric activation by the binding of AMP, AMPK can be activated by
upstream kinases such as LKB1 and CaMKK. Impaired exercise-stimulated glucose uptake in muscle-specific LKB1
knockout mouse models suggests that LKB1 may be the predominant kinase involved in regulation of AMPK by
contraction in skeletal muscle [14,15]. The relationship between AMPK and exercise tolerance has also been demon-
strated in AMPK-knockout mouse models. A skeletal muscle-specific AMPK knockout model demonstrated a re-
duced exercise capacity, as assessed by voluntary wheel running and treadmill running to exhaustion. Impaired mus-
cle function was indicated by a reduction in maximal force and fatigue resistance ex vivo [16]. It is also clear that
muscle function is closely dependent on metabolic function, particularly glucose uptake, as shown in GLUT4 knock-
out mouse models. These models show that when glucose uptake is impaired, susceptibility to fatigue in response to
exercise is enhanced [17,18]. Gorselink et al. [17] also showed that peak power output and contractile performance
were reduced in these mouse models. As observed in our ME/CFS skeletal muscle cell cultures, in response to con-
traction induced by EPS, both AMPK activation and glucose uptake is impaired [5]. We would predict that the lack of
effect on glucose uptake by EPSwould impairmuscle contractile function, leading to exercise intolerance. The current
study suggests that this failure to activate AMPK in response to contraction could be bypassed by pharmacological
intervention, and contributes to the evidence base for a clinical trial of an AMPK activator in ME/CFS.
Another key finding from the present study is the significant decrease in cellular ATP content in skeletal muscle
from ME/CFS compared with healthy controls. This decrease occurred regardless of treatment and was measured in-
dependently on two separate occasions. ReducedATP content has previously been observed post-exercise inME/CFS
patients [19] andmore recently, impairedATP synthesis has been observed in vivo in patients [20]. ATP content influ-
ences cell survival, with an age-related decrease in ATP content in cultured fibroblasts being linked with an increased
susceptibility to cell death by necrosis [21]. However, another study recently reported increased ATP levels in periph-
eral blood mononuclear cells from patients with ME/CFS [22]. These authors suggested that fatigue may be linked to
non-mitochondrial processes which produce ATP, such as glycolysis.
Potential causes of reduction in cellular ATP content include impairment in mitochondrial function, a decrease
in mitochondrial membrane potential or increased reactive oxygen/nitrogen species (ROS/RNS) production. Evi-
dence for a decrease in skeletal muscle mitochondrial function in ME/CFS is conflicting. Some studies have found
a decreased mitochondrial content, but not function in skeletal muscle biopsies from ME/CFS patients compared
with healthy controls [23], while others have identified metabolic abnormalities in ME/CFS consistent with impaired
mitochondrial function [24]. ROS may play an important role in the ability of skeletal muscle to adapt to exercise
but equally, increased ROS can impair mitochondrial function, reduce muscle contractile force, and contribute to
muscle dysfunction [25]. There is some evidence to suggest that oxidative stress pathways are activated in vivo in
ME/CFS [26,27] but, to our knowledge, this has not been examined in vitro. Future work will focus on exploring the
mechanisms by which contraction fails to activate AMPK and on mitochondrial function in skeletal muscle.
The important findings from the present study are that, firstly, pharmacological activation of AMPK can improve
glucose uptake in skeletalmuscle cell cultures frompatients withME/CFS and secondly, cellular ATP content is signif-
icantly reduced inME/CFSmuscle cell cultures. The observation that AMPKwas activated directly bymetformin and
991 but not EPS in the ME/CFS cultures points to a signalling defect proximal to AMPK. Further work is required
to delineate the defect and determine whether pharmacological activation of AMPK improves muscle function in
patients with ME/CFS.
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